Navigation Links
Cardo Medical, Inc. Announces Closing of $6.2 Million Private Placement
Date:11/16/2009

llaborates with leading surgeons around the country to create products that reduce or eliminate joint pain and allow patients to achieve more active lives. The company's cutting edge products are specifically developed with patients, surgeons and OR staff in mind and are designed to reduce operative time, enhance surgical technique, shorten hospital stays, reduce recovery time and improve outcomes. Cardo Medical's product portfolio includes devices for knee, hip, spinal fusion and motion preservation arthroplasty and replacement, many of which have already received FDA clearance. Cardo Medical has a robust and innovative product pipeline pending both USPTO and FDA submission and clearance.

Cardo Medical works in small, focused development teams in concert with physicians to rapidly develop products from concept to launch. We are committed to exceeding the standards by which any device company is judged. Please visit our website at www.cardomedical.com for more information on our complete portfolio of Reconstructive and Spinal Implant systems.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions regarding the business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would s
'/>"/>

SOURCE Cardo Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
2. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
3. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
4. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
5. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
6. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
7. Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc.
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Omeros Corporation (NASDAQ: OMER ) today ... to evaluate OMS824 in Huntington,s disease has been ... (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an ... to a wide range of diseases that affect ... shown promising results in animal models directly relevant ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, Inc., ... today that it will present new results on ... industry conference sponsored by the PML Consortium (composed ... JC polyomavirus (JCV) is the causative agent of ... kinase inhibitor in an extended release formulation, can ...
(Date:5/23/2013)... -- InspireMD, Inc. ("InspireMD" or the ... protection stents, today announced new 6-month results from ... trial demonstrating that the MGuard Embolic Protection Stent ... in all-cause mortality in ST segment elevation myocardial ... presented at the InspireMD STEMI Symposium at EuroPCR, ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... Therapeutics, Inc. (NASDAQ: HALO ) will be ... New York on Thursday, June 7, 2012 at 12:30 ... Financial Officer, Halozyme Therapeutics, will provide a corporate overview. ... The presentation will be webcast through the "Investors" section ...
... 31, 2012 /PRNewswire-iReach/ -- A January blog ... Institutes of Mental Health (NIMH), captured one of the core ... a divergence among members of the National Advisory Mental Health ... for funding by the NIMH. "Some members of ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference 2In basic science, sometimes it takes individual benefactors like Roys Poyiadjis to fuel innovation 2In basic science, sometimes it takes individual benefactors like Roys Poyiadjis to fuel innovation 3
(Date:5/23/2013)... Sika Sarnafil , the worldwide market leader in ... Systems of Iowa as the Recycling Project of the ... the re-roofing of the SuperTarget retail store in Olathe, ... contractor and one of Target’s Preferred Tier One roofing ... building practices and they are a worthy recipient of ...
(Date:5/23/2013)... Professional Insurance Plans, an independent insurance ... celebrate Fibromyalgia Education and Awareness Month. As a ... country, the agency feels that it is important for ... that affects an estimated 10 million of Americans. , ... definition of Fibromyalgia (FM) is, “a common and complex ...
(Date:5/23/2013)... 23, 2013 Traditionally, laser skin therapy ... on skins of colour, this can be tricky. Based ... 1-1V may be treated safely with most lasers. Darker ... discoloration issues, have been left without recourse. Those who ... “clear” their skin successfully. , Hyperpigmentation occurs ...
(Date:5/23/2013)... , , THURSDAY, May 23 (HealthDay News) -- Statins are ... but the medications also could hamper heart patients, ability ... A small group of overweight or obese people ... taking a 40 milligram daily dose of simvastatin, while ... same exercise regimen did show improvement, found the study ...
(Date:5/23/2013)... PTSD , Soldiers returning home from combat may ... disorder if public support for a war effort is ... shapes the level of distress soldiers feel from the ... two experiments that asked participants to exterminate woodlice in ... actor show either interest or disgust for the act ...
Breaking Medicine News(10 mins):Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2Health News:Vancouver Skin Care Clinic Successfully Clears Pigmentation in Skin of Colour 2Health News:Vancouver Skin Care Clinic Successfully Clears Pigmentation in Skin of Colour 3Health News:Statins May Hamper Workout Results 2Health News:Statins May Hamper Workout Results 3Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 2Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 3
... Spanish . , The PhD, defended ... the Basque Country, proposes a series of recommendations that ... professionals who treat terminal cancer patients. , Autonomy is ... armed with knowledge about the causes of the illness, ...
... talk and ... care about digestive health, WHITE PLAINS, ... advertising campaign for Activia featuring award-winning,actress and passionate self-esteem advocate ... air throughout 2008, Curtis draws attention,to the importance of digestive ...
... Named National, Spokesperson for The Leukemia & Lymphoma Society,s 2008 Light The ... ... March 3 Rob Brown, who stars in the,upcoming drama The Express as ... to win the Heisman,Trophy, is the national spokesperson for The Leukemia & Lymphoma ...
... The Providence Service,Corporation (Nasdaq: PRSC ) today ... its fourth quarter and year ended December 31, 2007,on ... Providence will hold a conference call at 11:00 a.m. ... Thursday, March 13, 2008 to discuss its,financial results and ...
... CEL-SCI CORPORATION,(Amex: CVM ) provided details ... groundbreaking activities currently underway at its,manufacturing facility near ... Multikine(R), the Company,s lead compound, for a pivotal,Phase ... untreated head,and neck cancer patients. The facility, which ...
... ... Hospitals, TEL AVIV, ... digital templating software, will,launch its unique Orthoweb on-line service at the ... in San,Francisco (Booth #349, Hall A)., "This is a real ...
Cached Medicine News:Health News:Factors that enhance autonomy of cancer patients 2Health News:Factors that enhance autonomy of cancer patients 3Health News:Dannon Activia Launches Thought-Provoking Advertising Campaign Featuring Jamie Lee Curtis 2Health News:Dannon Activia Launches Thought-Provoking Advertising Campaign Featuring Jamie Lee Curtis 3Health News:Actor Rob Brown Rushes to Gain Ground Against Blood Cancer 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 3Health News:CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial 2Health News:Orthocrat to Launch On-Line Service for Storing and Sharing Pre-Operative Data at AAOS 2
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... coated with a thin layer ... the surface slick as glass ... prevent debris from collecting on ... For partial stenosis. Silicone with ...
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Medicine Products: